<h2 id="emergent-biosolutions-keeps-facility-investment-close-to-home">Emergent BioSolutions Keeps Facility Investment Close to Home</h2>

<p>Biopharmaceutical company Emergent BioSolutions opened a new facility in Baltimore, Maryland, in July 2010. The facility houses multiple manufacturing suites designed to support clinical and commercial manufacture of the company’s anthrax and tuberculosis products.  Emergent BioSolutions planned to invest over $8 million in the project, which is expected to create 120 jobs over five years. </p>

<blockquote>
  <p><strong><em>“The Baltimore facility symbolizes Emergent’s continued investment in manufacturing as one of its core competencies and competitive advantages; it is also a testament to Emergent’s commitment to the State of Maryland, where we are proud to be a key contributor to economic development and job growth.”</em></strong></p>

  <p>-Fuad El-Hibri, CEO Emerent BioSolutions</p>
</blockquote>

<p>Emergent employs approximately 180 people in Maryland, which is home not only to the Baltimore manufacturing facility but also to the company’s corporate headquarters and one of its product development sites. </p>

<p>Recently <a href="http://www.bizjournals.com/baltimore/print-edition/2012/06/22/emergent-biosolutions-to-expand.html">Emergent announced it is expanding its facilities in Baltimore and Gaithersburg, Maryland</a> as a part of a $220 million public-private partnership with the U.S. Department of Health and Human Services.</p>
